India Today|July 06, 2020
Since news broke on June 21 that pharmaceutical company Glenmark’s Favipiravir formulation FabiFlu had been cleared by the DCGI (Drug Controller General of India) for ‘restricted emergency use’ in ‘mild to moderate cases’, Govind has received daily inquiries about the medicine. It didn’t seem to matter that Favipiravir, like Remdesivir before it, was not a guaranteed treatment for COVID.
“People just hear ‘new COVID cure’ and think there is new hope, better recovery prospects,” says Dr. T. Narayanan, president of the Indian Pharmaceutical Association. But to think of these new drugs as ‘cures’ elides the caveat that “they have not been found to be effective in severe cases—the stage at which inflammation and thrombosis become hard to treat”. ‘Mild to moderate’ cases, which account for the bulk of COVID positives, typically have a high likelihood of recovering on their own.
You can read up to 3 premium stories before you subscribe to Magzter GOLD
Log in, if you are already a subscriber
Get unlimited access to thousands of curated premium stories and 5,000+ magazines
READ THE ENTIRE ISSUE
July 06, 2020